Cognition Therapeutics
CGTXCognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company based in the United States. The company's business is focused on the discovery and development of small molecule therapeutics designed to treat neurodegenerative and neuro-ophthalmic disorders. Its primary therapeutic target is Alzheimer's disease, with its lead candidate, CT1812, in clinical development for this indication. The company's pipeline is centered on targeting the sigma-2 (σ-2) receptor complex, which is implicated in pathways that lead to neuronal damage. Cognition Therapeutics' lead investigational product, CT1812, is an orally delivered, brain-penetrant small molecule designed to modulate this receptor. This candidate has progressed to multiple Phase 2 clinical studies, including the SHINE and SHIMMER trials, which are evaluating its safety and efficacy in individuals with mild-to-moderate Alzheimer's disease. Beyond Alzheimer's disease, Cognition Therapeutics is exploring the application of its σ-2 receptor platform in other conditions characterized by proteinopathies. This includes clinical-stage investigation in dementia with Lewy bodies and preclinical research in geographic atrophy, an advanced form of age-related macular degeneration. The company's research and development activities are supported by grants from organizations such as the National Institute on Aging and the Alzheimer's Association.
CGTX · Stock Price
Historical price data
About
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company based in the United States. The company's business is focused on the discovery and development of small molecule therapeutics designed to treat neurodegenerative and neuro-ophthalmic disorders. Its primary therapeutic target is Alzheimer's disease, with its lead candidate, CT1812, in clinical development for this indication. The company's pipeline is centered on targeting the sigma-2 (σ-2) receptor complex, which is implicated in pathways that lead to neuronal damage. Cognition Therapeutics' lead investigational product, CT1812, is an orally delivered, brain-penetrant small molecule designed to modulate this receptor. This candidate has progressed to multiple Phase 2 clinical studies, including the SHINE and SHIMMER trials, which are evaluating its safety and efficacy in individuals with mild-to-moderate Alzheimer's disease. Beyond Alzheimer's disease, Cognition Therapeutics is exploring the application of its σ-2 receptor platform in other conditions characterized by proteinopathies. This includes clinical-stage investigation in dementia with Lewy bodies and preclinical research in geographic atrophy, an advanced form of age-related macular degeneration. The company's research and development activities are supported by grants from organizations such as the National Institute on Aging and the Alzheimer's Association.